Technical Analysis for AMAG - AMAG Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 11.96 2.22% 0.26
AMAG closed up 1.92 percent on Tuesday, October 22, 2019, on 42 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.

Earnings due: Oct 30

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical AMAG trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 2.22%
Crossed Above 20 DMA Bullish 2.22%
Crossed Above 50 DMA Bullish 2.22%
Bollinger Band Squeeze Range Contraction 2.22%
Doji - Bearish? Reversal 2.22%
BB Squeeze Started Range Contraction 2.22%
20 DMA Resistance Bearish 4.18%
NR7 Range Contraction 4.18%
Inside Day Range Contraction 4.18%
20 DMA Resistance Bearish 6.74%

Older signals for AMAG ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, engages the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA). The company's principal product includes Feraheme (ferumoxytol) injection for intravenous (IV) use, which was approved for marketing in the United States in June 2009 by the U.S. Food and Drug Administration, for use as an IV iron replacement therapy for the treatment of IDA in adult patients with chronic kidney disease (CKD). The company also markets Feraheme in Canada, the European Union, and Switzerland. In addition, its development projects comprise Feraheme for patients with IDA regardless of the underlying cause, which has completed Phase III clinical program. The company sells Feraheme primarily to authorized wholesalers and specialty distributors. AMAG Pharmaceuticals, Inc. has a license, development, and commercialization agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Feraheme/Rienso as a therapeutic agent in Europe, certain Asia-Pacific countries, the Commonwealth of Independent States, Canada, India, and Turkey; and collaboration and exclusive license agreement with 3SBio for the development and commercialization of Feraheme as a therapeutic agent in China for an initial indication for the treatment of IDA in patients with CKD and an option to expand into additional therapeutic indications. The company was founded in 1981 and is headquartered in Lexington, Massachusetts.
Health Biopharmaceutical Medication Chronic Kidney Disease European Union
Is AMAG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 23.03
52 Week Low 6.81
Average Volume 895,383
200-Day Moving Average 11.8983
50-Day Moving Average 11.5589
20-Day Moving Average 11.5113
10-Day Moving Average 11.291
Average True Range 0.5893
ADX 13.1
+DI 22.6921
-DI 15.0993
Chandelier Exit (Long, 3 ATRs ) 11.2321
Chandelier Exit (Short, 3 ATRs ) 12.5129
Upper Bollinger Band 12.3684
Lower Bollinger Band 10.6542
Percent B (%b) 0.61
BandWidth 14.891454
MACD Line -0.0561
MACD Signal Line -0.0482
MACD Histogram -0.0079
Fundamentals Value
Market Cap 412.87 Million
Num Shares 35.3 Million
EPS -1.30
Price-to-Earnings (P/E) Ratio -9.00
Price-to-Sales 0.90
Price-to-Book 0.57
PEG Ratio 0.30
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.63
Resistance 3 (R3) 12.63 12.31 12.48
Resistance 2 (R2) 12.31 12.07 12.31 12.43
Resistance 1 (R1) 12.00 11.92 12.16 12.01 12.37
Pivot Point 11.69 11.69 11.76 11.69 11.69
Support 1 (S1) 11.38 11.45 11.53 11.39 11.03
Support 2 (S2) 11.06 11.30 11.07 10.97
Support 3 (S3) 10.76 11.06 10.92
Support 4 (S4) 10.77